By rray, 2 August, 2024 Exclude Patient Type Detail Header No Detail Type Text Detail Text Consider individual risks benefits race FHx comorbidities risks of dx tx 9 etc nbsp nbsp High risk if age 50 yo 6 10 prostate CAs are found in pts 65 yo 11 African American or Caribbean of African ancestry 2A 8 11 12 FHx of prostate CA esp sibling11 even AUA6 and ASCO7 discourage screening in pts w NCCN 12 Testing after 75 yo should be done only in very healthy people w little or no comorbidity esp if they ve never had PSA testing or their PSA is rising 2B to detect the small number of aggressive CAs that would pose significant risk if left undetect USPSTF 2 Counsel pts 70 yo who request screening of its darr likelihood of benefit uarr risk of false positive test results and potential dx and tx complications Follow same guidance in transgender women regardless of hormone tx or gender affirming surgery 13 14 if digital exam indicated neovaginal approach may be more effective than rectal 14 Patient Type Detail Header (Long) Screening considerations